Physician profile
John Bermingham
NPI 1700847910
$3,659.51
in general payments reported to CMS, 2019-2025
30 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $590 · 2021: $671 · 2022: $1,039 · 2023: $133 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $747.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $729.77 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.03 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $250.65 | 2019-2022 | |
| Philips North America LLC | $213.77 | 2019-2023 | |
| United Therapeutics Corporation | $191.58 | 2021-2025 | Tyvaso |
| Amgen INC. | $156.45 | 2022-2023 | Tezspire |
| Mylan Specialty L.P. | $141.60 | 2019-2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $114.21 | 2019-2021 | |
| Genzyme Corporation | $94.37 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $74.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $65.15 | 2019-2022 | |
| Electromed, INC. | $63.06 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $61.85 | 2021-2023 | Xywav |
| Insmed, INC. | $58.97 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $58.82 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $55.03 | 2022 | |
| Advanced Respiratory, INC | $52.78 | 2020 | |
| Baxter Healthcare | $40.94 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $28.95 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.33 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.98 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $23.11 | 2021-2022 | |
| Resmed Corp | $19.84 | 2025 | |
| Pulmonx Corporation | $19.78 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Mallinckrodt Hospital Products INC. | $18.93 | 2022 | |
| Shire North American Group INC | $14.97 | 2019 | |
| Genentech USA, INC. | $13.64 | 2019 | |
| Harmony Biosciences LLC | $12.86 | 2022 | |
| Eisai INC. | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bermingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.